Releases

Print
2013
2012
2011
2010
2009
Archives

Category:

All
ı
Corporate Releases
ı
Press Releases
ı
Releases in Danish
Dec 18, 2009
Corporate Releases

Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia - planning for continued clinical work

Dec 11, 2009
Corporate Releases

Financial calendar 2010

Dec 9, 2009
Press Releases

EU Commission inspection in Lundbeck Italy

Nov 27, 2009
Corporate Releases

Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease

Nov 10, 2009
Corporate Releases

Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities

Nov 4, 2009
Corporate Releases

Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities

Nov 3, 2009
Corporate Releases

Third quarter 2009 report - Lundbeck records 20% growth, driven by Lundbeck Inc. and key products

Nov 2, 2009
Corporate Releases

Lundbeck starts clinical phase IIa with Lu AA24493 (cEPO) in Friedreich's ataxia in a study also assessing efficacy via biomarkers

Oct 30, 2009
Corporate Releases

Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline

Oct 27, 2009
Press Releases

Lundbeck commended for climate change disclosure

Oct 9, 2009
Press Releases

Lundbeck receives important award in the USA for its effort

Oct 9, 2009
Press Releases

Lundbeck appoints new Vice President for finished goods

Oct 6, 2009
Press Releases

Lundbeck consolidates its global production capacity

Sep 23, 2009
Press Releases

Lundbeck to launch efficiency improvement programme

Sep 23, 2009
Corporate Releases

Results of ADAGIO study with Azilect® in Parkinson's disease published in The New England Journal of Medicine

Sep 4, 2009
Press Releases

Lundbeck to strengthen its development organisation

Aug 21, 2009
Press Releases

Lundbeck appoints new manager in China

Aug 21, 2009
Corporate Releases

FDA grants marketing approval for Lundbeck's Sabril® (vigabatrin)

Aug 13, 2009
Corporate Releases

Second quarter 2009 report - Lundbeck records 18% revenue growth. Double digit growth in all regions

Jul 31, 2009
Press Releases

Lundbeck appoints new Chief Procurement Officer

Jul 31, 2009
Corporate Releases

Total number of voting rights and size of share capital as of 31 July 2009 after reduction of the share capital of H. Lundbeck A/S

Jul 30, 2009
Corporate Releases

Pipeline update - following an interim analysis the studies with bifeprunox for the treatment of schizophrenia is discontinued

Jul 7, 2009
Press Releases

Lundbeck strengthens its research capabilities by acquiring ground-breaking Danish technologies

Jul 7, 2009
Corporate Releases

Lundbeck increases its share of Xenazine® and strengthens the U.S. profitability - transaction immediately accretive

Jul 2, 2009
Corporate Releases

Lu AA24530 shows positive results in major depressive disorder phase II study

Jun 25, 2009
Corporate Releases

Lundbeck receives FDA Complete Response Letter on Serdolect® for the treatment of schizophrenia

Jun 11, 2009
Corporate Releases

Update on Lundbeck Inc. (USA)

Jun 8, 2009
Corporate Releases

Update on Lu AA21004 clinical development programme in major depressive disorder (MDD)

May 18, 2009
Corporate Releases

Lundbeck provides update on NDA for Serdolect® for the treatment of schizophreni

May 13, 2009
Corporate Releases

First quarter 2009 report. Double digit revenue growth. Strong performance by key products

Apr 27, 2009
Corporate Releases

Articles of association for H. Lundbeck A/S

Apr 21, 2009
Corporate Releases

H. Lundbeck A/S held its Annual General Meeting on 21 April 2008 at the company's registered office

Apr 7, 2009
Corporate Releases

FDA Advisory Committee provides opinion on Serdolect® for the treatment of schizophrenia

Apr 2, 2009
Corporate Releases

Notice of the annual general meeting

Mar 19, 2009
Corporate Releases

Lundbeck's acquisition of Ovation Pharmaceuticals cleared by US Federal Trade Commission

Mar 12, 2009
Corporate Releases

Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities

Mar 9, 2009
Corporate Releases

Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities

Mar 4, 2009
Corporate Releases

Annual report 2008 - Lundbeck meets all of its financial forecasts for 2008 and expects continuing growth in 2009

Mar 4, 2009
Corporate Releases

Annual Report 2008

Feb 9, 2009
Corporate Releases

Lundbeck to acquire US-based Ovation Pharmaceuticals, Inc. - a specialty pharmaceutical company focusing on central nervous system disorders (CNS)

Jan 29, 2009
Press Releases

Lundbeck recording growth in Spain - strong growth propels escitalopram to a market-leading position

Jan 27, 2009
Corporate Releases

Lundbeck to divest non-strategic investments to the Lundbeck Foundation

Jan 14, 2009
Press Releases

Lundbeck to intensify focus on new products

Jan 7, 2009
Press Releases

Lundbeck appoints new and experienced HR manager

You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.